Zoe Tharin

Chalon-sur-saone, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial.

FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial.

Journal: Future oncology (London, England)

Published: February 06, 2025

Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

Journal: Signal transduction and targeted therapy

Published: September 02, 2024

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Journal: Oncogene

Published: March 16, 2023

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Journal: Oncogene

Published: October 08, 2022

Smartphone-based application and nurses' interventions for symptoms monitoring in patients treated with oral anticancer agents: A 1-year follow-up in a tertiary cancer center.

Smartphone-based application and nurses' interventions for symptoms monitoring in patients treated with oral anticancer agents: A 1-year follow-up in a tertiary cancer center.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: August 08, 2022

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.

Journal: Scientific reports

Published: June 04, 2022

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.

Journal: Pharmaceutics

Published: September 08, 2021

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.

Journal: Cancers

Published: July 27, 2021

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma.

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma.

Journal: Cancers

Published: February 18, 2021

Utility of exome sequencing in routine care for metastatic colorectal cancer.

Utility of exome sequencing in routine care for metastatic colorectal cancer.

Journal: Molecular and clinical oncology

Published: January 04, 2021

Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer.

Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer.

Journal: Journal of gastrointestinal oncology

Published: December 14, 2020

Influence of primary tumor location and resection on survival in metastatic colorectal cancer.

Influence of primary tumor location and resection on survival in metastatic colorectal cancer.

Journal: World journal of gastrointestinal oncology

Published: June 08, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026